managing side effects: antipsychotic...
TRANSCRIPT
www.mghcme.org
Managing Side Effects: Antipsychotic Agents
David C. Henderson, MD Associate Professor of Psychiatry and Epidemiology
Massachusetts General Hospital Harvard Medical School
Harvard school of Public Health
www.mghcme.org
David C. Henderson, MD
Forum Pharmaceuticals, Norvartis Research grant
Global Psychiatry CME Speaker Fee
Mclean Hospital Speaker Fee
Reckitt Benckiser Advisory Board
“My spouse/partner and I have the following relevant financial relationship with a commercial interest to disclose:”
www.mghcme.org
APA Treatment Selection Guide
ARI & ZIP Weight or metabolic
YES Recurrent nonadherence
YES, except RIS Prolactin sensitivity
YES, except RIS EPS sensitivity
YES YES Tardive dyskinesia
YES Hostility/aggression
YES Suicide risk
YES 1st episode
Group 4: Long Acting
Group 3: CLZ
Group 2: 2nd Generation
Group 1: 1st Generation
Patient Profile
Lehman AF et al. Am J Psychiatry. 2004;161(suppl 2):1-51. Reprinted with permission from the American Journal of Psychiatry (Copyright 2004). American Psychiatric Association.
www.mghcme.org
Usually gradual Incomplete efficacy
Usually fast Usually effective Response to adjunctive therapy?
No* Yes Response to dose lowering?
Low High Specificity to antipsychotic?
Yes Yes Physical findings?
Obesity EPS
*Within doses prescribed for schizophrenia; most studies do not show dose relation; those that do show statistical significance would not usually be clinically significant. Newcomer JW. CNS Drugs. 2005;19(suppl 1):1-93; Weiden PJ. Postgrad Med. 2006 Special Report (September):627-644; Weiden PJ. J Psychiatri Pract. 2007;13-24.
Treatment Approach Varies by Side Effect: Example of EPS Vs Obesity
www.mghcme.org
Frequency of Side Effects: Atypical Antipsychotics
Side Effect Aripiprazole Clozapine Olanzapine Quetiapine Risperidone Ziprasidone
Weight gain ± +++ +++ + + ±
Extrapyramidal symptoms
± to + ± ± to +* ± ± to +* ± to +*
Tardive dyskinesia ± (?) ± ± (?) ± (?) ± to + ± (?)
Diabetes mellitus ± +++ +++ + + ±
Dyslipidemia ± +++ +++ ++ + ±
QTC prolongation ± ++ + + + ++
Decrease in orthostatic BP
± +++ + ++ ++ ±
Elevated prolactin level
± ± ± ± +++ ±
Somnolence ± +++ + ++ ± ±
McIntyre RS, Konarski JZ. J Clin Psychiatry. 2005;66(suppl 3):28
* = dose related; (?) = not clearly established; ± = no to minimal, + = occasional, ++ = frequent, +++ = substantial occurrence of side effect compared with placebo rates
www.mghcme.org
Rank Order of Side Effects Eliciting Moderate-to-Severe Distress
4037.3
33.230.8
18.8 18.4
0
10
20
30
40
50
Akinesia Weight Gain Anticho- linergic
Sexual Problems
Muscle Rigidity
Akathisia
Patie
nts R
epor
ting*
(%)
(N=9
9)
*Reporting when side effect is present. Weiden PJ, Miller AL. J Psychiatr Prac. 2001;7:41-47.
www.mghcme.org
Adverse Events Caused by Blockade of Other, Nondopamine Receptors
Satiety blockade 5-HT2c
[Less EPS] 5-HT2A
Hypotension α1-adrenergic
Sedation, weight gain H1
Dry mouth, constipation, tachycardia blurred vision, urinary retention
M2-5 (peripheral)
Memory, cognition M1 (central)
Adverse Events Receptors
Gardner DM et al. CMAJ. 2005;172:1703-1711; Shayegan DK, Stahl SM. CNS Spectr. 2004;9(10 suppl 11):6-14; McEvoy JP, Freter S. Comp Psychiatry; 1989;30:135-138; Mori K et al. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:659-665; Sweeney JA et al. Psychiatr Res. 1991;37:297-308; Velligan DI et al. Schizophren Res. 2002;53:239-248.
www.mghcme.org
Anticholinergic Load As a Cause of Cognitive Impairment in Schizophrenia
*P<.05; †P<.01. Minzenberg et al. Am J Psychiatry. 2004;161:116-124.
*
† †
0.15 0.16 0.14
0.24
0.35 0.35
0
0.1
0.2
0.3
0.4
Pharmacologic Estimate Clinical Estimate
Corr
elat
ion
"General" IQ
Attention
Memory
www.mghcme.org
Conventional Antipsychotic Side Effects at Therapeutic Doses
• Extrapyramidal Side Effects (EPS) – Rigidity – Bradykinesia – Tremor – Akathisia
• Tardive Dyskinesia (TD) – Late-onset movements of the tongue, face,
neck, trunk and/or limbs
• Increased Prolactin – Galactorrhea – Amenorrhea
Practice guideline for the treatment of patients with schizophrenia, 2nd edition. APA; 2004. Available at: http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf. Accessed March 13, 2007.
www.mghcme.org
Annualized TD Risk With Antipsychotics
Correll CU et al. Am J Psychiatry. 2004;161(3):414 TD = tardive dyskenesia
www.mghcme.org
Sexual Dysfunction and Antipsychotics
• Antipsychotics can affect sexual dysfunction directly or indirectly, especially in men
• Directly – Binding to dopaminergic, histaminergic,
cholinergic, and α-adrenergic receptors may inhibit motivation and reward, increase sedation, and reduce peripheral vasodilation
• Indirectly – D2 receptor blockade in tuberoinfundibular tract can
increase serum prolactin levels, which in turn can affect sexual function
Baggaley M. Hum Psychopharmacol. 2008;23(3):201
www.mghcme.org
Prolactin and Sexual Dysfunction During Quetiapine and Risperidone Treatment
Prolactin (ng/mL) 13.8 + 17.9 57.9 + 39.7 .000
Libido 16% 36% .05
Erection 11% 33% .05
Lubrication 6% 38% .05
Orgasm 5% 30% .01
Ejaculatory dysfunction 14% 29% .18
Quetiapine Risperidone (n=25) (n=26) P
Knegtering R et al. J Clin Psychopharmacol. 2004;24(1):56
Query: Prolactin line of chart has odd number placement. Is +17.9 and +39.7 the CI? Editorial
www.mghcme.org
Mortality in Schizophrenia
Reduced Life Expectancy in Schizophrenia
Antipsychotic-related weight gain and obesity, impaired glucose tolerance and new onset diabetes, hyperlipidemia, and cardiovascular disease
Comorbidities
- Diabetes Mellitus - Cardiovascular disease - Cancer
Lifestyle Choice
- Unhealthy Diet - Lack of physical activity - Excessive Smoking - Alcohol Abuse
High risk of Suicide and accidents
Physical illnesses diagnosed late and
treated insufficiently
The overall mortality rate is two to three times as high for patients with schizophrenia as it is for the general population, resulting in a life expectancy of about 20 years less of the general population* *Laursen TM, et al. Annual review of clinical psychology 2014; 10: 425-48
www.mghcme.org 14
Henderson et al, Lancet Psychiatry 2014
www.mghcme.org
Cumulative Effect of Small Daily Errors in Energy Balance
Energy expenditure
(kcal/y)
Energy intake (kcal/y)
1 million
1 million
0
Excess intake (% total) Excess intake (kcal/d)
0 0.5 1 5 12 kcal/d 25 kcal/d 125 kcal/d
Change in body fat (kg/year)
0 2 4 6
Rosenbaum M et al. N Engl J Med. 1997;337:396-407.
www.mghcme.org
Different Metabolic Syndrome Definitions
Metabolic syndrome if *≥3 criteria are met; †≥2 criteria are met in the presence of obligatory waist criterion; or ‡on antihypertensive drugs; or §on antihyperglycemic drugs. ATP = Adult Treatment Panel; ATPA = Adult Treatment Panel–adjusted; IDF = International Diabetes Federation. NCEP ATPIII. JAMA. 2001;285:2486-2497; Grundy SM et al. Circulation. 2004;110:227-239; International Diabetes Federation. Available at: http;//www.idf.org. Accessed April 20, 2007.
Men: <40 Women: <50
Men: <40 Women: <50
Men: <40 Women: <50
HDL-C (mg/dL)
≥100 ≥100 ≥110 Blood glucose (mg/dL)§
≥150 ≥150 ≥150 TG (mg/dL)
≥130/85 ≥130/85 ≥130/85 BP (mm Hg)‡
Men: ≥94/37 Women: ≥80/31
OBLIGATORY
Men: >102/40 Women: >88/35
Men: >102/40 Women: >88/35
Waist (cm/inch)
IDF† ATP III A* ATP III* Criteria
www.mghcme.org
Subcutaneous Fat
Abdominal Muscle Layer
Intra-abdominal Fat
Visceral Adiposity: The Critical Adipose Depot
www.mghcme.org
Prevalence of the metabolic syndrome in adults: NHANES III. Arch Intern Med 2003;163:427-436.
www.mghcme.org
Ethnic Differences in Triglyceride Levels and HDL-Cholesterol
• Black adults and children have a better lipid profile- lower triglyceride and higher HDL
• The effects of insulin resistance on lipid profile were the same in whites and blacks, TG should be higher and HDL lower
• Differences in diet do not account for this • Lipoprotein lipase (LPL) are higher and hepatic lipase are
lower in blacks • Insulin resistance (IR) does not seem to impair LPL in blacks
so can clear triglyceride with IR • May explain the lower rates of metabolic syndrome and
criteria not set to identify high risk for DM and cardiovascular disease.
Sumner AE: J Pediatri 2009; 155:S7.e7-11; Gaillard et al. Ethn Dis 2009 Spring:19:S2-1-7
www.mghcme.org
Antipsychotic-Associated Differences in Insulin Sensitivity
*P<.001; non-obese patients with schizophrenia, matched on BMI (P=.81), but not leptin (P<.001); hip-waist ratio (P=.04) or subscapular skinfold (P=.049). IVGTT = intravenous glucose tolerance test. Henderson DC et al. Arch Gen Psychiatry. 2005;62:19-28.
Insulin Sensitivity By Medication IVGTT With Minimal-Model Analysis
Insu
lin S
ensi
tivity
(X
10-
4 • min
-1 • m
l-1)
0
5
10
15
CLZ (n=12)
OLZ (n=12)
RIS (n=12)
3.2 4.5
11.7*
www.mghcme.org
Association of Insulin Resistance With CV Risk Factors and Atherosclerosis
AGEs = advanced glycosylation end products; VCAM = vascular cell adhesion molecule; NO = nitric oxide; PAI = plasminogen activator inhibitor; tPA = adenosine triphosphatase; CRP = C-reactive protein; IL = interleukin.
Atherosclerosis
Glucose Intolerance
•AGEs Hypertension
Dyslipidemia •Low HDL
•Small, dense LDL particles
•Hypertriglyceridemia
Endothelial dysfunction •VCAM, E-selectin
•NO
Impaired thrombosis
•PAI-1 •tPA
Inflammation •CRP • IL-6
Insulin resistance
McFarlane SI et al. J Clin Endocrinol Metab. 2001;86:713-718.
Obesity
www.mghcme.org
.0075 11.2 21.7 .9635 14.2 14.1 Glucose criterion
.0001 26.8 46.9 .0001 31.1 47.2 BP criterion
.0001 36.3 63.3 .0001 31.9 48.9 HDL criterion
.0001 19.6 42.2 .0001 32.1 50.7 Triglyceride criterion
.0001 57.0 76.3 .0001 24.8 35.5 Waist circumference criterion
.0001 25.1 51.6 .0001 19.7 36.0 Metabolic syndrome prevalence
P NHANES III (%) (N=180)
CATIE (%) (N=180) P NHANES (%)
(N=509) CATIE (%) (N=509)
Women Men
CATIE = Clinical Antipsychotic Trials of Intervention Effectiveness; NHANES = National Health and Nutrition Examination Survey. McEvoy JP et al. Schizophr Res. 2005;80:19-32. Copyright Schizophrenia International Research Society 2005.
Fasting CATIE vs Matched NHANES III Subjects
www.mghcme.org
Incidence of metabolic disorders in children receiving second-generation antipsychotic vs albuterol treatment
Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW. Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics & Adolescent Medicine. In press.
CI: confidence interval. * indicates p<0.05 and ** indicates p<0.01 for the comparison between the antipsychotic and albuterol cohorts. Data from California, Missouri, and Oregon state Medicaid programs of children initiating drug treatment in 2005. Antipsychotic and albuterol users had no recognized diabetes or dyslipidemia at the start of therapy. Metabolic disturbances were ascertained for six months after the index start date.
www.mghcme.org
Henderson DC et al. J Clin Psychiatry. 2007;68:533-541.
New-onset Diabetes Mellitus Known Diabetes Mellitus
New-Onset and Known Diabetes Presenting as Diabetic Ketoacidosis in Schizophrenia Patients Treated With
Atypical Antipsychotics
0
2
4
6
8
10
12
14
16
Mea
n H
bA1c
(%)
0
200
400
600
800
1000
1200
Mea
n G
luco
se (m
g/dL
)
n=11 n=10 n=11 n=10
Mean Glucose Mean HbA1c
www.mghcme.org
Odds Ratios of Substandard Medical Care in Mentally Ill Outpatients With Diabetes
Data from 313,586 veteran outpatients with diabetes, 25% of whom had mental disorders. SUD = substance use disorder. Frayne et al. Arch Intern Med. 2005;165:2631-2638. Copyright © 2000 American Medical Association. All rights reserved.
Depression
Anxiety
Psychosis
Manic
SUD
Personality
0.8 1.0 1.2 1.4 1.6 0.8 1.0 1.2 1.4 1.6 0.8 1.0 1.2 1.4 1.6 0.8 1.0 1.2 1.4 1.6 0.8 1.0 1.2 1.4 1.6 0.8 1.0 1.2 1.4 1.6 No HbA1c Test Done
No LDL Test Done
No Eye Exam Done
No Monitoring Poor Glycemic Control
Poor Lipemic Control
www.mghcme.org
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
www.mghcme.org
Assessment of Early Weight Gain: A Simple Predictive Tool for Overall Weight-Gain Risk
Age: rapid-weight gain (RWG): 35.6 < non–rapid-weight gain (NRWG): 39.3, P<.0001; BMI: RWG, 23.9 < NRWG, 26.4, P<.0001. Kinon BJ et al. J Clin Psychopharmacol. 2005;25:255-258. Copyright © 2005 Lippincott Williams & Wilkins. All rights reserved.
RWG: ≥7% Δ at 6 weeks NRWG: <7% Δ at 6 weeks NRWG: 0% < Δ< 7% at 6 weeks NRWG: ≤0% Δ at 6 weeks
n=183, 15%
n=615
n=274
n=889, 85%
0 10 20 30 40 50 60
6 Weeks
LS M
ean
Wei
ght Δ
(kg)
Week
14 12 10
8 6
4 2 0
–4
–4
www.mghcme.org
Weight Gain with Combination Treatments: Quetiapine and Divalproex
0
1
2
3
4
5
Mea
n W
eigh
t Gai
n (k
g)
Group
Quetiapine + divalproex Placebo + divalproex
6-week, double-blind, randomized comparison of quetiapine + divalproex vs divalproex alone in 30 adolescents with bipolar mania.
Weight Gain
4.2
2.5
DelBello MP, et al. J Am Acad Child Adolesc Psychiatry. 2002;41:1216-1223.
www.mghcme.org
0
1
2
3
4
5
6
Wei
ght G
ain
(lb)
Group
Placebo + MS Risperidone + MS Haloperidol + MS
P<0.004 vs placebo.
Sachs GS, et al. J Psychiatry. 2002;159:1146-1154.
0.3
5.3
1.1
3-week, double-blind, randomized comparison of risperidone, placebo, or haloperidol added to mood stabilizer (MS) — divalproex or lithium — in 156 patients with bipolar mania.
Weight Gain with Combination Treatments: Risperidone and Haloperidol
www.mghcme.org
• Switch agents: best results to date • Education from the onset of treatment • Diet and nutrition programs • Exercise programs: walking, etc. • Pharmacologic agents (?): prevention vs following
significant weight gain – Sibutramine, orlistat (FDA approved) – Antihistaminic agents (nizatidine) – Amantadine – Topiramate – Buproprion – Metformin
Weight Gain Interventions
www.mghcme.org
www.mghcme.org Klein DJ, et al. Am J Psychiatry. 2006;163:2072-2079.
Change in Weight and BMI in Children Taking SGAs Plus Placebo or Metformin
www.mghcme.org
Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized
Controlled Trial
-15
-10
-5
0
5
Lifestyle +Metformin
Metformin Lifestyle +Placebo
Placebo
Weight FBS Insulin
N = 128
12-week placebo-controlled trial, metformin 750 mg/day
Chan
ge fr
om B
asel
ine
Wu RR, et al. JAMA 2008;299:185-193
www.mghcme.org
Predicted Long-Term Changes in Weight When Switching Between Newer Antipsychotics
↑ weight ↑ weight ↑↑ weight ≈ weight ZIP
↓ weight ≈ weight ↑ weight ↓ weight RIS
↓ weight ≈ weight ↑ weight ↓ weight QUE
↓↓ weight ↓ weight ↓ weight ↓↓ weight OLZ
≈ weight ↑ weight ↑ weight ↑↑ weight ARI
ZIP RIS QUE OLZ ARI
Post-switch
Pre-
switc
h
IMPORTANT: Much of the data on weight loss and lipid improvements comes from switch studies with presumably selected patients experiencing mixture of efficacy and tolerability difficulties with prior medication. Weiden PJ. Postgrad Med. 2006 Special Report(September):27-44.
www.mghcme.org
Predicted Δ in Metabolic Risk Factors When Switching Newer Antipsychotics
?≈ lipids ↑ lipids ↑↑ lipids ≈ lipids ZIP
?≈ lipids ?↑ lipids ↑ lipids ≈ lipids RIS
↓ lipids ?≈ lipids ↑ lipids ↓ lipids QUE
↓↓ lipids ↓ lipids ↓ lipids ↓↓ lipids OLZ
≈ lipids ≈ lipids ↑ lipids ↑↑ lipids ARI
ZIP RIS QUE OLZ ARI
Post-switch
IMPORTANT: Much of the data on weight loss and lipid improvements comes from switch studies with presumably selected patients experiencing mixture of efficacy and tolerability difficulties with prior medication. Weiden PJ. Postgrad Med. 2006;Special Report(September):27-44.
Pre-
switc
h
www.mghcme.org
Consensus Statement on Antipsychotic Drugs, Obesity, and Diabetes: Monitoring Protocol for Patients on 2nd-
Generation Antipsychotics*
*More frequent assessments may be warranted based on clinical status. Copyright © 2004 American Diabetes Association. From Diabetes Care®, Vol. 27, 2004; 596-601. Reprinted with permission from The American Diabetes Association.
[X] X X X Fasting lipid profile
X X X Fasting plasma glucose
X X X Blood pressure
X X Waist circumference
X X X X X Weight (BMI)
X X Personal/family history
Every 5 y Annually* Quarterly 12 wk 8 wk 4 wk Baseline
Long-Term Short-Term
www.mghcme.org
Weight Loss/Maintenance Therapy vs Standard of Care
127 146 Total Test for heterogeneity: chi2=69.64, df=8, P=<.0001, I2=88.5% Test for overall effect: z=18.59, P<.00001
Test for heterogeneity: chi2=3.54, df=5, P=.62, I2=0.0% Test for overall effect: z=3.05, P=.002
136 138 Total
Pharmacological Weight Loss Therapy
Pharmacological Weight Gain Prevention Therapy
Cognitive Behavior Weight Loss Therapy
Test for heterogeneity: chi2=0.59, df=1, P=.44, I2=0.0% Test for overall effect: z=4.65, P<.00001
46 58 Total
Test for heterogeneity chi2=1.76, df=2, P=.41, I2=0.0% Test for overall effect z=4.65, P=.002
58 71 Total
Cognitive Behavior Weight Gain Prevention Therapy*
Control Group (n) Tx Group (n) Study
*Medium-term; In 2 studies lasting 6 months: –4.87 [–7.11, –2.64]. Faulkner et al. Cochrane.Database.Syst.Rev. 2007;1:CD005148.
–5.0 0 –7.5 2.5 5.0 –2.5 7.5
Favors Tx Favors Control
Weighted Mean Difference (Fixed)
[95% CI]
Weighted Mean Difference (Fixed)
[95% CI]
–3.38 [–4.81, –1.96]
–1.69 [–2.77, –0.61]
–1.16 [–1.90, 0.41]
–3.85 [–4.25, –3.44]
www.mghcme.org
Weight Loss study (Daumit et al. , New England J Med, 2013)
• 291 participants who underwent randomization, – 58.1% had schizophrenia or a schizoaffective disorder,
22.0% had bipolar disorder, and 12.0% had major depression.
– At baseline, the mean was 36.3; mean weight was 225.9 lb). Data on weight at 18 months were obtained from 279 participants.
– At 18 months, the mean between-group difference in weight (change in intervention group minus change in control group) was −3.2 kg (−7.0 lb, P=0.002); 37.8% of the participants in the intervention group lost 5% or more of their initial weight, as compared with 22.7% of those in the control group (P=0.009).
38
www.mghcme.org
12-Step Healthy Lifestyle Program
• Skip breakfast • Consume fast food >1 per wk • Consume saturated or processed fat-free food • Watch TV, play computer games
≥2 hours/day
• Replace sugar-containing drinks with water
• Eat 4 to <6 meals, with <2 meals in the evening or night
• Serve small meal portions • Eat slowly, drink water, take seconds only
after delay • Eat food with a low glycemic index (<55) • Consume >25–30 grams of soluble fiber per
day • Snack only when hungry and use fruit or
vegetables • Perform moderate physical activity for >30–
60 min/day
Do Not’s Do’s
Correll CU, Carlson HE. J Am Acad Child Adolesc Psychiatry. 2006;45: 771-791.
www.mghcme.org
Effect of Interventions to Reduce CHD Risk
-8-14
-27-30 -30
-45 -45
-60
-80
-60
-40
-20
0
CH
D R
isk
(%)
BMI by 1 pt
Smoking Cessation
DBP by 6 mm Hg (>140/90)
TC by 10% (TC 180–
200 mg/dL Weight by 4–10 kg
LDL by 30 mg/dL (any LDL)
Healthy Weight
(BMI 18.5–25)
Active Lifestyle (≥20 min
walk)
Li TY et al. Circulation. 2006;113:499-506; Hennekens CH. Circulation. 1998;97:1095-1102; Rich-Edwards JW et al. N Engl J Med. 1995;332:1758-1766; Bassuk SS, Manson JE. J Appl Physiol. 2005;99:1193-1204; Grundy SM. Circulation. 2004;110:227-239; Critchley JA, Capewell S. JAMA. 2003;290:86-97..
www.mghcme.org
AE Prevention/Management
• Careful choice of drug (based on history, individual risk profile, pharmacologic characteristic of medications)
• Information provided to px/so’s (psychoeducation—individual, groups, etc.)
• Monitoring (include baseline status!)
• Dose reduction • Add-on treatment
(eg, anticholinergics, statins, sildenafil, etc.) • Switching antipsychotic • Making risk/benefit profile a regular topic • Lifestyle interventions
Psychopharmacology Friday, September 28 – Sunday, September 30, 2012
The Westin Copley Place
39th Annual Psychopharmacology Conference Thursday – Sunday, October 22– 25, 2015
The Westin Copley Place MGHCME.ORG
Massachusetts General Hospital Department of Psychiatry
Presents
39th Annual Psychopharmacology
Conference
THURSDAY-SUNDAY, OCTOBER 22-25, 2015 THE WESTIN COPLEY PLACE
BOSTON, MA